Briefing
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults (D-ALBA / GIMEMA LAL2116)
Chemo-free induction/consolidation with dasatinib followed by blinatumomab in adults with newly diagnosed Ph-positive ALL, with molecular MRD as a central response measure. Single-arm (level 2). Long-term results: Foà et al., J Clin Oncol 2024 (PMID 38127722).
- Design: paper
- Assay: Molecular MRD in Ph+ ALL